<i>In vitro</i> and <i>in vivo</i> evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies

Edward B. Garon, David Sawcer, P. Thomas Vernier, Tao Tang, Yinghua Sun, Laura Marcu, Martin A. Gundersen, H. Phillip Koeffler

International Journal of Cancer · 2007 · 173 citations · 20 references

Concepts

TL;DR

Nanoelectropulses are brief, high‑field electric pulses that primarily trigger intracellular effects in cells. The study aims to evaluate nanoelectropulse therapy as a potential local treatment for cancer. The authors pulsed 5 hematologic and 16 solid‑tumor cell lines in vitro to assess cytotoxicity. Nanoelectropulses killed over 60 % of hematologic cells and reduced viability by >10 % in 10 of 16 solid‑tumor lines, with the AsPC‑1 pancreatic line showing a 64 % drop; in vivo, 4 of 6 AsPC‑1 xenografts regressed, including 3 complete responses, and a single human basal‑cell carcinoma patient achieved a complete pathological response, indicating broad antitumor efficacy.

Abstract

When delivered to cells, very short duration, high electric field pulses (nanoelectropulses) induce primarily intracellular events. We present evidence that this emerging modality may have a role as a local cancer therapy. Five hematologic and 16 solid tumor cell lines were pulsed in vitro. Hematologic cells proved particularly sensitive to nanoelectropulses, with more than a 60% decrease in viable cells measured by MTT assay 96 hr after pulsing in 4 of 5 cell lines. In solid tumor cell lines, 10 out of 16 cell lines had more than a 10% decrease in viable cells. AsPC-1, a pancreatic cancer cell line, demonstrated the greatest in vitro sensitivity among solid tumor cell lines, with a 64% decrease in viable cells. When nanoelectropulse therapy was applied to AsPC-1 tumors in athymic nude mice, responses were seen in 4 of 6 tumors, including clinical complete responses in 3 of 6 animals. A single human subject applied nanoelectropulse therapy to his own basal cell carcinoma and had a complete pathologic response. In summary, we demonstrate that electric pulses 20 ns or less kill a wide variety of human cancer cells in vitro, induce tumor regression in vivo, and show efficacy in a single human patient. Therefore, nanoelectropulse therapy deserves further study as a potentially effective cancer therapy.

References

20